10 These side effects are typical for all anticholinergics, and did not differ from those reported in previous surveys. Efcacy The overactive bladder symptom score (OABSS) data before treatment with propiverine hydrochloride and at weeks 4, 8, and 12 of treatment, are shown in the table below together with the effects of treatment on various symptom scores. Conclusion The mean OABSS was 8.92 before previous anticholinergic therapy, 7.92 before treatment with propiverine hydrochloride, and 5.48 at nal evaluation after 12 weeks of treatment on propiverine hydrochloride. This study showed that switching to propiverine hydrochloride is a viable option when patients receive an inadequate treatment response on solifenacin succinate, imidafenacin or tolterodine tartrate. Treatment with propiverine hydrochloride improved the OABSS more markedly than the previous anticholinergics and OABSS improved signicantly for all types of urinary incontinence (urge, mixed, and stress). This effect was observed at all time points and in all subgroups stratied by sex, age, symptoms, and previous anticholinergics. Patients who experienced adverse drug reactions on previous anticholinergic treatment are likely to experience the same adverse events when treated with propiverine hydrochloride. In patients with benign prostatic hyperplasia, propiverine hydrochloride should be used with caution, as voiding difculty may be exacerbated, and residual urine may be increased. Event (MedDRA patient preferred term) Total number of subjects Thirst Constipation Urinary retention Voiding difculty Residual urine volume increased Dry mouth Dizziness Overactive bladder symptom score (OABSS) OABSS in male participants OABSS in female participants Day-time frequency score Night-time frequency score Urgency score Urgency incontinence score Number of subjects with adverse drug reactions 480 184 151 44 38 31 17 12 Before treatment 2932 1610 1322 2932 2932 2932 2932 Incidence of adverse drug reactions (%) 13.25 5.08 4.17 1.21 1.05 0.86 0.47 0.33 Week 4 2668 1458 1210 2663 2667 2662 2665 Number of subjects who discontinued treatment 232 70 56 26 30 13 8 9 Week 8 2078 1165 913 2073 2077 2073 2072 Treatment discontinuation rate (%) 6.40 1.93 1.55 0.72 0.83 0.36 0.22 0.25 Week 12 1823 1001 822 1819 1822 1817 1818 Analysis set: subjects included in the safety evaluation (n = 3624) Analysis set: subjects included in efcacy evaluation (n = 2932) UROLOGY, URO-ONCOLOGY AND SEXOLOGY UPDATE
RkJQdWJsaXNoZXIy NTIyOTQ=